Literature DB >> 9054942

A mouse model for the learning and memory deficits associated with neurofibromatosis type I.

A J Silva1, P W Frankland, Z Marowitz, E Friedman, G S Laszlo, D Cioffi, T Jacks, R Bourtchuladze, G Lazlo.   

Abstract

Neurofibromatosis type I (NF1) is one of the most commonly inherited neurological disorders in humans, affecting approximately one in 4,000 individuals. NF1 results in a complex cluster of developmental and tumour syndromes that include benign neurofibromas, hyperpigmentation of melanocytes and hamartomas of the iris. Some NF1 patients may also show neurologic lesions, such as optic pathway gliomas, dural ectasia and aqueduct stenosis. Importantly, learning disabilities occur in 30% to 45% of patients with NF1, even in the absence of any apparent neural pathology. The learning disabilities may include a depression in mean IQ scores, visuoperceptual problems and impairments in spatial cognitive abilities. Spatial learning has been assessed with a variety of cognitive tasks and the most consistent spatial learning deficits have been observed with the Judgement of Line Orientation test. It is important to note that some of these deficits could be secondary to developmental abnormalities and other neurological problems, such as poor motor coordination and attentional deficits. Previous studies have suggested a role for neurofibromin in brain function. First, the expression of the Nf1 gene is largely restricted to neuronal tissues in the adult. Second, this GTPase activating protein may act as a negative regulator of neurotrophin-mediated signalling. Third, immunohistochemical studies suggest that activation of astrocytes may be common in the brain of NF1 patients. Here, we show that the Nf1+/- mutation also affects learning and memory in mice. As in humans, the learning and memory deficits of the Nf1+/- mice are restricted to specific types of learning, they are not fully penetrant, they can be compensated for with extended training, and they do not involve deficits in simple associative learning.

Entities:  

Mesh:

Year:  1997        PMID: 9054942     DOI: 10.1038/ng0397-281

Source DB:  PubMed          Journal:  Nat Genet        ISSN: 1061-4036            Impact factor:   38.330


  96 in total

1.  Posttranscriptional regulation of gene expression in learning by the neuronal ELAV-like mRNA-stabilizing proteins.

Authors:  A Quattrone; A Pascale; X Nogues; W Zhao; P Gusev; A Pacini; D L Alkon
Journal:  Proc Natl Acad Sci U S A       Date:  2001-09-25       Impact factor: 11.205

Review 2.  Molecular and cellular mechanisms of learning disabilities: a focus on NF1.

Authors:  C Shilyansky; Y S Lee; A J Silva
Journal:  Annu Rev Neurosci       Date:  2010       Impact factor: 12.449

Review 3.  Genetic architecture of declarative memory: implications for complex illnesses.

Authors:  Carrie E Bearden; Katherine H Karlsgodt; Peter Bachman; Theo G M van Erp; Anderson M Winkler; David C Glahn
Journal:  Neuroscientist       Date:  2011-08-10       Impact factor: 7.519

4.  Disruption of Critical Period Plasticity in a Mouse Model of Neurofibromatosis Type 1.

Authors:  Mariska van Lier; M Hadi Saiepour; Koen Kole; Juliette E Cheyne; Nawal Zabouri; Thomas Blok; Yi Qin; Emma Ruimschotel; J Alexander Heimel; Christian Lohmann; Christiaan N Levelt
Journal:  J Neurosci       Date:  2020-06-11       Impact factor: 6.167

5.  Neurofibromin is the major ras inactivator in dendritic spines.

Authors:  Ana F Oliveira; Ryohei Yasuda
Journal:  J Neurosci       Date:  2014-01-15       Impact factor: 6.167

6.  HCN channels are a novel therapeutic target for cognitive dysfunction in Neurofibromatosis type 1.

Authors:  A Omrani; T van der Vaart; E Mientjes; G M van Woerden; M R Hojjati; K W Li; D H Gutmann; C N Levelt; A B Smit; A J Silva; S A Kushner; Y Elgersma
Journal:  Mol Psychiatry       Date:  2015-04-28       Impact factor: 15.992

7.  Neurocognitive outcomes in neurofibromatosis clinical trials: Recommendations for the domain of attention.

Authors:  Karin S Walsh; Jennifer Janusz; Pamela L Wolters; Staci Martin; Bonita P Klein-Tasman; Mary Anne Toledo-Tamula; Heather L Thompson; Jonathan M Payne; Kristina K Hardy; Peter de Blank; Claire Semerjian; Laura Schaffner Gray; Sondra E Solomon; Nicole Ullrich
Journal:  Neurology       Date:  2016-08-16       Impact factor: 9.910

Review 8.  Optimizing biologically targeted clinical trials for neurofibromatosis.

Authors:  David H Gutmann; Jaishri O Blakeley; Bruce R Korf; Roger J Packer
Journal:  Expert Opin Investig Drugs       Date:  2013-02-21       Impact factor: 6.206

Review 9.  Impaired synaptic plasticity in RASopathies: a mini-review.

Authors:  Florian Mainberger; Susanne Langer; Volker Mall; Nikolai H Jung
Journal:  J Neural Transm (Vienna)       Date:  2016-08-26       Impact factor: 3.575

10.  Cardiac and vascular functions of the zebrafish orthologues of the type I neurofibromatosis gene NFI.

Authors:  Arun Padmanabhan; Jeong-Soo Lee; Fraz A Ismat; Min Min Lu; Nathan D Lawson; John P Kanki; A Thomas Look; Jonathan A Epstein
Journal:  Proc Natl Acad Sci U S A       Date:  2009-12-04       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.